Cryptococcal meningitis in patients with autoimmune hemolytic anemia

Area of Science:

• Infectious Diseases
• Hematology
• Clinical Medicine

Background:

• Autoimmune hemolytic anemia (AIHA) is an autoimmune disorder characterized by antibody-mediated destruction of red blood cells.
• Cryptococcal meningitis (CM) is a serious opportunistic infection, particularly in immunocompromised individuals.
• The co-occurrence of AIHA and CM presents unique clinical challenges and necessitates specific management strategies.

Purpose of the Study:

• To elucidate the epidemiology, clinical characteristics, treatment, and outcomes of cryptococcal meningitis in patients with autoimmune hemolytic anemia.
• To establish a reference for the prevention and control of CM in AIHA patients.
• To identify risk factors associated with CM in the AIHA population.

Main Methods:

• A retrospective analysis of five cases of CM in AIHA patients treated between 2003 and 2013.
• Inclusion of eight additional related foreign cases for comprehensive evaluation.
• Identification and genotyping of clinical isolates of Cryptococcus neoformans var. grubii (VNI genotype, serotype A).

Main Results:

• Common clinical features include headache, nausea, and fever, often with non-specific early manifestations leading to diagnostic delays.
• Identified risk factors for CM in AIHA patients include long-term prednisone use (≥15 mg/day), poor anemia control, and splenectomy.
• All clinical isolates were identified as Cryptococcus neoformans var. grubii, VNI genotype, serotype A.

Conclusions:

• Cryptococcal meningitis in AIHA patients requires vigilant monitoring due to non-specific initial symptoms.
• Proactive management of anemia and judicious use of corticosteroids are crucial for preventing CM in AIHA.
• Combination therapy with intravenous amphotericin B and oral 5-fluorocytosine is the recommended treatment for AIHA-complicated CM.